| NCT ID | NCT05960890 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jiangsu Taizhou People's Hospital |
| Condition | Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2023-06-08 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,000 participants in total. It began in 2023-06-08 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about the influencing factors of chronic heart failure prognosis in heart failure patients. The main question it aims to answer is that what are the influencing factors of clinical outcomes in chronic heart failure. Participants will be collected multiple omics data such as phenotype group, environmental exposure group, intestinal microbiome, genome, metabolome, and noninvasive biomarkers.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years; 2. Fulfill at least one of the following criteria：①History of chronic heart failure;②New-onset heart failure with LVEF \<50%；③New-onset heart failure with LVEF≧50%，E/e'≧15 and BNP\>400 pg/mL/NT-proBNP(\<50 years, \>450 pg/mL; 50\~75 years, \>900 pg/mL; \>75 years, \>1800 pg/mL) 3. Etiology: dilated cardiomyopathy, hypertensive heart disease, ischaemic cardiomyopathy, Non-severe valvular heart disease； 4. Primary post-discharge therapy: oral medication; 5. Sign the informed consent form. Exclusion Criteria: 1. Patients with renal failure (Ccr\<30ml/min) or patients on dialysis therapy; 2. Various correctable secondary causes of cardiac insufficiency including hyperthyroid heart disease, anaemic heart disease, uncorrected congenital heart disease; severe valvular heart disease (including severe stenosis or closure of organic aortic and mitral valves); 3. Patients with indications for pacemaker implantation but have not received a pacemaker implant; 4. Patients with chronic obstructive pulmonary disease accompanied by type II respiratory failure. 5. Patients who cannot understand and sign an informed consent form. 6. Patients with mental illness, pregnant women, and other special populations.
Contact & Investigator
Ming Chu, Doctor
PRINCIPAL INVESTIGATOR
Jiangsu Taizhou People's Hospital
Frequently Asked Questions
Who can join the NCT05960890 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05960890 currently recruiting?
Yes, NCT05960890 is actively recruiting participants. Contact the research team at 2567181759@qq.com for enrollment information.
Where is the NCT05960890 trial being conducted?
This trial is being conducted at Taizhou, China.
Who is sponsoring the NCT05960890 clinical trial?
NCT05960890 is sponsored by Jiangsu Taizhou People's Hospital. The principal investigator is Ming Chu, Doctor at Jiangsu Taizhou People's Hospital. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.